文献速递新发突发、热带与寄生虫病细菌感染、耐药与抗菌药物

缅甸青蒿素耐药恶性疟流行区社区随机试验: Mass Drug Administration加速消除疟疾

Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial.
PubMed 文献 · Lancet Infect Dis · 2021-06-18

在缅甸克伦邦青蒿素耐药恶性疟流行区开展整群随机试验,评估双氢青蒿素哌喹群体给药(MDA)的安全性和效果。

要点

  • MDA加速降低恶性疟患病率,第3个月效果显著,第10个月差异未达统计学显著。
  • 在低传播、青蒿素耐药疫点,MDA可作为社区病例管理和蚊帐发放的补充加速消除。

核心结论

  • 在低传播环境中,MDA可加速社区病例管理带来的恶性疟患病率下降,且安全性可接受。
  • 疟疾消除规划应考虑在高传播疫点使用MDA快速降低恶性疟患病率。

研究设计与样本

  • 在缅甸克伦邦农村社区开展整群随机对照试验,共16个集群(8对),按恶性疟患病率配对后1:1随机分配至MDA组或对照组。
  • 所有集群均提供常规疟疾病例管理和长效杀虫蚊帐;主要结局为第3个月和第10个月恶性疟患病率。

关键数值与推荐

  • 纳入MDA操作适宜的村庄需满足:成人疟疾(所有虫种)患病率>30%或恶性疟患病率>10%(或两者兼有)。

临床怎么用

  • 在青蒿素耐药恶性疟低传播疫点,可在社区病例管理和蚊帐发放基础上考虑加用MDA快速降低患病率。
  • MDA实施需监测头晕、皮疹等不良事件,本试验未观察到治疗相关死亡。

局限性

  • 分组分配未设盲。
  • 第10个月恶性疟患病率差异未达统计学显著,远期效果需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To contain multidrug-resistant Plasmodium falciparum, malaria elimination in the Greater Mekong subregion needs to be accelerated while current antimalarials remain effective. We evaluated the safety, effectiveness, and potential resistance selection of dihydroartemisinin-piperaquine mass drug administration (MDA) in a region with artemisinin resistance in Myanmar. METHODS: We did a cluster-randomised controlled trial in rural community clusters in Kayin (Karen) state in southeast Myanmar. Malaria prevalence was assessed using ultrasensitive quantitative PCR (uPCR) in villages that were operationally suitable for MDA (villages with community willingness, no other malaria control campaigns, and a population of 50-1200). Villages were eligible to participate if the prevalence of malaria (all species) in adults was greater than 30% or P falciparum prevalence was greater than 10% (or both). Contiguous villages were combined into clusters. Eligible clusters were paired based on P falciparum prevalence (estimates within 10%) and proximity. Community health workers provided routine malaria case management and distributed long-lasting insecticidal bed-nets (LLINs) in all clusters. Randomisation of clusters (1:1) to the MDA intervention group or control group was by public coin-flip. Group allocations were not concealed. Three MDA rounds (3 days of supervised dihydroartemisinin-piperaquine [target total dose 7 mg/kg dihydroartemisinin and 55 mg/kg piperaquine] and single low-dose primaquine [target dose 0·25 mg base per kg]) were delivered to intervention clusters. Parasitaemia prevalence was assessed at 3, 5, 10, 15, 21, 27, and 33 months. The primary outcomes were P falciparum prevalence at months 3 and 10. All clusters were included in the primary analysis. Adverse events were monitored from the first MDA dose until 1 month after the final dose, or until resolution of any adverse event occurring during follow-up. This trial is registered with ClinicalTrials.gov, NCT01872702. FINDINGS: Baseline uPCR malaria surveys were done in January, 2015, in 43 villages that were operationally suitable for MDA (2671 individuals). 18 villages met the eligibility criteria. Three villages in close proximity were combined into one cluster because a border between them could not be defined. This gave a total of 16 clusters in eight pairs. In the intervention clusters, MDA was delivered from March 4 to March 17, from March 30 to April 10, and from April 27 to May 10, 2015. The weighted mean absolute difference in P falciparum prevalence in the MDA group relative to the control group was -10·6% (95% CI -15·1 to -6·1; p=0·0008) at month 3 and -4·5% (-10·9 to 1·9; p=0·14) at month 10. At month 3, the weighted P falciparum prevalence was 1·4% (0·6 to 3·6; 12 of 747) in the MDA group and 10·6% (7·0 to 15·6; 56 of 485) in the control group. Corresponding prevalences at month 10 were 3·2% (1·5 to 6·8; 34 of 1013) and 5·8% (2·5 to 12·9; 33 of 515). Adverse events were reported for 151 (3·6%) of 4173 treated individuals. The most common adverse events were dizziness (n=109) and rash or itching (n=20). No treatment-related deaths occurred. INTERPRETATION: In this low-transmission setting, the substantial reduction in P falciparum prevalence resulting from support of community case management was accelerated by MDA. In addition to supporting community health worker case management and LLIN distribution, malaria elimination programmes should consider using MDA to reduce P falciparum prevalence rapidly in foci of higher transmission. FUNDING: The Global Fund to Fight AIDS, Tuberculosis and Malaria.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. McLean ARD, Indrasuta C, Khant ZS, et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infect Dis. 2021. PMID: 34147154. doi:10.1016/S1473-3099(20)30997-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。